SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 56 of 94
Word Count: 1235
Character Count: 8001

Document Content:

2013 to 2018, as well as chairman of the governance committee and as a member of the audit committee. Orchids Paper Products Company filed for Chapter 11 bankruptcy on April 1, 2019, in the U.S. Bankruptcy Court for the District of Delaware; ● been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, by any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity; ● been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

●	been
the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged
violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions
or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution,
civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting
mail or wire fraud or fraud in connection with any business entity; or

●	been
the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization
(as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange
Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons
associated with a member.

From
time to time, we may be subject to various legal or administrative claims and proceedings arising in the ordinary course of business.
Litigation or any other legal or administrative proceeding, regardless of the outcome, is likely to result in substantial cost and diversion
of our company’s resources, including our company’s management’s time and attention.

EXECUTIVE
AND DIRECTOR COMPENSATION

The
following table sets forth the aggregate compensation paid to our named executive officers for the fiscal years ended December 31, 2025
and 2024. Individuals we refer to as our “named executive officers” include our Chief Executive Officer and our two other
most highly compensated executive officers who were serving as executive officers at the end of the fiscal year ended December 31, 2025
and whose total compensation for services rendered in all capacities exceeded $100,000 during the fiscal year ended December 31, 2025.

Summary
Compensation Table

Name and Principal Position Year Salary ($) Bonus ($) Stock Awards ($)(2) Option Awards ($)(2) Non-Equity Incentive Plan Compensation ($) Nonqualified Deferred Compensation Earnings ($) All Other Compensation ($) Total ($)

David Richmond, Chairman and Co-Chief Executive Officer (6) 2025 $	300,000 - $	- $	8,900 - - $	36,176	(3) $	345,076

Steve Chartier, President, Co-Chief Executive Officer and Director 2025 $	375,000 $	50,000 $	- $	9,881 - - $	97,059	(4) $	531,940

Ori Ben-Yehuda, Chief Medical Officer 2025 - - $	- $	563 - - $	120,000	(5) $	120,563

(1)	This
amount reflects the pay out of unused vacation time for 2024.

(2)	Amounts
reflect the full grant-date fair value of restricted stock and stock option awards granted during the applicable fiscal year computed
in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named executive officer. We provide information
regarding the assumptions used to calculate the value of all awards made to our named executive officers in Note 9 of the Consolidated
Financial Statements.

(3)	This
amount includes medical insurance of $32,552.

(4)	This
amount includes medical insurance of $63,569 and matching contributions in our 401(k) plan of $29,625.

(5)	Consulting
fees as our CMO is a consultant, paid monthly in arrears.

Richmond resigned from his position as chief financial officer on April 28, 2026.

Employment
Arrangements with our Executive Officers and Directors

Current
Arrangements

Richmond is currently employed pursuant to an offer letter agreement with the Company that became effective January 15, 2025 (the “Richmond
Offer Letter”). Pursuant to the Richmond Offer Letter, Mr. Richmond serves as the Co-Chief Executive Officer of the Company, reporting
to the board of directors. The Richmond Offer Letter contains the following compensatory terms: (i) an annual base salary of $300,000,
(ii) eligibility to receive a discretionary bonus of up to 30% of his base salary, contingent upon the achievement of objectives mutually
agreed upon with the board of directors, and (iii) an option to purchase 191,000 shares of the Company’s common stock, which vests
as to 25% of the underlying shares on the first anniversary of the effective date of the award agreement, with the remaining 75% vesting
in equal monthly installments over the following 36 months, subject to Mr. Richmond’s continued employment. The options fully vest
upon a change in control of the Company. In the event the Company terminates Mr. Richmond’s employment without “cause”
or Mr. Richmond terminates his employment for “good reason” (each, as defined in the Richmond Offer Letter), Mr. Richmond
is entitled to receive severance equal to twelve months of his then-current base salary.

Chartier is currently employed pursuant to an offer letter agreement with the Company that became effective December 3, 2024 (the “Chartier
Offer Letter”). Pursuant to the Chartier Offer Letter, Mr. Chartier serves as the Co-Chief Executive Officer and President of the
Company, reporting to the board of directors. The Chartier Offer Letter contains the following compensatory terms: (i) an annual base
salary of $375,000, (ii) eligibility to receive a discretionary bonus of up to 30% of his base salary, contingent upon the achievement
of objectives mutually agreed upon with the board of directors, (iii) a sign-on bonus of $50,000, and (iv) an option to purchase 220,000
shares of the Company’s common stock, which vests as to 25% of the underlying shares on the first anniversary of the effective
date of the award agreement, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to Mr.
Chartier’s continued employment. The options fully vest upon a change in control of the Company. In the event the Company terminates
Mr. Chartier’s employment without “cause” or Mr. Chartier terminates his employment for “good reason” (each,
as defined in the Chartier Offer Letter), Mr. Chartier is entitled to receive severance equal to twelve months of his then-current base
salary.

Ben-Yehuda is engaged as a consultant pursuant to a consulting agreement that became effective September 20, 2022 (the “Ben-Yehuda
Consulting Agreement”). The Ben-Yehuda Consulting Agreement has an open term and entitles Dr. Ben-Yehuda to $500 per hour of work
plus all reasonable pre-approved out-of-pocket expenses. The Ben-Yehuda Consulting Agreement may be terminated by either party upon ten
days’ written notice. Additionally, the Ben-Yehuda Consulting Agreement contains standard confidentiality and indemnification provisions
and a six-month post-engagement non-solicitation clause.

Carl Byrnes entered into an employment agreement
with the Company, effective April 28, 2026 (the “Byrnes Agreement”). Under the agreement, Mr. Byrnes serves as the Company’s
Chief Financial Officer and reports to our Board.